Addex Therapeutics Profit Margin

The latest profit margin for ADXN is -3212.5% as of March 2026. That compares with 5081.44% in the prior-year period — down 163.2% year over year. That is below the Healthcare sector average of 13.71%. Investors often review this figure alongside Addex Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADXN's profit margin moved from 5081.44% to -3212.5% — a 163.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Addex Therapeutics's valuation or profitability profile.

Against Healthcare companies, ADXN currently prints -3212.5% for profit margin, while the sector average sits near 13.71%. That is roughly 23530.4% below the sector mean. Large gaps often invite a closer look at Addex Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Addex Therapeutics converts resources into returns. At -3212.5%, ADXN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 5081.44% in the prior-year period — down 163.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADXN's profit margin (-3212.5%), review year-over-year change from 5081.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.